Frequently Asked Questions
The market is segmented based on , By Drug Type (Riluzole, Edaravone (Radicava), Glutamate Receptor Antagonist and Others), Disease Type (Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, Multifocal Motor Neuropathy and Others), Diagnosis (EMG/NCS, Serum and Urine Electrophoresis, Serum Immunoelectrophoresis, Quantitative Immunoglobulins, Anti-GM1 Antibody Levels), Treatment Type (Neurotherapy, Chemotherapy, Cell Therapy and Others), Route of Administration (Oral, Injection, Transdermal), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2030.
.
The Global Anterior Horn Cell Disease Market size was valued at USD 0.70 USD Billion in 2022.
The Global Anterior Horn Cell Disease Market is projected to grow at a CAGR of 4.5% during the forecast period of 2023 to 2030.
The major players operating in the market include Sanofi, Novartis AG, Mitsubishi Chemical Group Corporation, BrainStorm Cell Limited, Ionis Pharmaceuticals, Genervon Biopharmaceuticals LLC, Bausch Health Companies , F. Hoffmann La Roche , Treeway B.V., CYTOKINETICS, AB Science, ADVANZ PHARMA, Biogen, Orphazyme, KRIGLE PHARMA , Aquestive Therapeutics , Apotex .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
